Cardiac markers: present and future
Tóm tắt
In the early twentieth century, acute myocardial infarction secondary to acute thrombotic coronary occlusion was considered a rare, fatal condition. Acute myocardial infarction is now one of the most-common serious illnesses in the industrialized world. Laboratory medicine now plays a crucial role in identifying risk factors, early events, and conditions triggering plaque rupture in coronary ischemic disease. However, the greatest progress in laboratory research has resulted from the discovery of new and more-promising biochemical markers of myocardial damage. The discovery of cardiac troponins, in particular, has heralded a new age in the diagnosis and treatment or management of a broad spectrum of diseases, grouped together under the heading ofacute coronary syndrome, and including stable and unstable angina, and non-Q wave infarction to Q-wave infarction. Cardiac troponins, which are selectively released by damaged myocardiocytes, have a specificity that has not only allowed an improvement in the diagnosis of acute cardiac ischemic disorders, but has also enabled us to make a more-reliable stratification of risk and prediction of outcome. It is generally agreed that two biochemical markers should be used: an early marker (and we recommed myoglobin for this) and a definitive marker, which is cardiac troponin (I or T). Future research is likely to include the standardization of methods for measuring current markers, troponin I in particular, the assessment of rapid bedside tests, and the investigation of the relationship between cardiac markers and emerging immunological and coagulation parameters. Thrombogenesis is now recognized as important in the final process of coronary atherosclerosis, and new markers of thrombogenesis should be used to evaluate the risk of plaque rupture and to monitor the outcome of thrombolytic therapy. Moreover, recent vascular biology studies have provided information on the developmental stages of atherosclerosis and emphasized the importance of the endothelium as a modulator of vascular reactivity, atherogenesis, and plaque stability. The different types of laboratory test (biochemical, immunological, and coagulative) now available, should soon allow improvement in the diagnosis and therapy of ischemic coronary diseases.
Tài liệu tham khảo
Braunwald E. Evolution of the management of acute myocardial infarction: a 20th century saga. Lancet 1998; 352: 1771.
Pardes H, Manton KG, Lander ES, Tolley HD, Ullian AU, Palmer H. Effects of medical research on health care and economy. Science 1999; 283: 36.
Thomas L. The lives of a cell. Bantam, New York, 1975.
Weisbrod A. Health care and economy. J Econ Lit 1991; 29: 523.
Kannel WB, Dawber TR, Kagan A, Revotskic N, Stokes J. Factors of risk in the development of coronary heart disease: six years follow-up experience. Ann Intern Med 1961; 55: 35.
Doyle JT, Dawber TR, Kannel WB, Heslin AS, Kahan HA. Cigarette smoking and coronary heart disease: combined and experience of the Albany and Framingham studies. N Engl J Med 1962; 266: 796.
National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 1994; 89: 1333.
The sixth report of the Joint National Committee. Prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1998; 158: 573.
National Center of Health Statistics. Health United States 1996–1997: injury chartbook. Hyattsville, Md: National Center of Health Statistics 1997; 183: 190.
National Center of Health Statistics, Division of Vital Statistics. Public use data tapes for U.S. mortality, 1970 to 1995 and provisional tabulations for 1996. Hyattsville, Md.: National Center of Health Statistics, 1997.
National Heart, Lung and Blood Institute. Morbidity and mortality: 1996 chartbook on cardiovascular, lung, and blood diseases. Bethesda, Md.: National Institute of Health 1996.
Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998; 339: 861.
Levy D, Thom TJ. Death rates from coronary disease — progress and a puzzling paradox. N Engl J Med 1998; 339: 915.
Antmann EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, ed. Heart disease. Philadelphia: Saunders; 1997: 1184–1288.
Lee TH, Rouan GW, Weisberg MC, Brand DA, Cook EF, Acamora D, Goldman L. Sensitivity of routine clinical criteria for diagnosing myocardial infarction within 24 h of hospitalization. Ann Intern Med 1987; 106: 181.
Hooper RJL. Pathology and laboratory medicine: cardiac markers. Ann Clin Biochem 1999; 36: 262.
Plebani M, Zaninotto M. Diagnostic strategies using myoglobin measurement in myocardial infarction. Clin Chim Acta 1998; 272: 69.
Plebani M, Zaninotto M. Diagnostic strategies in myocardial infarction using myoglobin measurement. Eur Heart J 1998; 19 [Supl N]: N12.
Bhayana V, Cohoe S, Leung F, et al. Diagnostic evaluation of creatine kinase-2 mass and creatine kinase-3 and -2 isoform ratios of early diagnosis of acute myocardial infaction. Clin Chem 1993; 39: 488.
Mair J, Morandell D, Genser N, et al. Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction. Clin Chem 1995; 41: 1266.
Secchiero S, Altinier S, Zaninotto M, Lachin M, Plebani M. Evaluation of a new automated system for the determination of CK-MB isoforms. J Clin Lab Anal 1995; 9: 359.
Zaninotto M, Altinier S, Lachin M, Plebani M. Carboxypeptidase N and creatine kinase-MB isoforms in acute myocardial infarction. Eur J Clin Chem Clin Biochem 1997; 35: 291.
Vuori J, Syrjala H, Vaananen HK. Myoglobin-carbonic anhydrase III ratio: highly specific and sensitive early indicator for myocardial damage in acute myocardial infarction. Clin Chem 1996; 42: 107.
Van Nieuwenhoben FA, Kleine AH, Wodzig KWH, et al. Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acidbinding protein. Circulation 1994; 92: 2848.
Rabitzsch G, Mair J, Lechleitner P, et al. Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 1995; 41: 966.
Frey N, Muller-Bardorff M, Katus HA. Myocardial damage: the role of troponin T. In: Kaski JC, Holt DW, eds. Myocardial damage: early detection by novel biochemical markers. Doldrecht: Kluwer; 1998: 27–39.
Plebani M, Panteghini M. Troponin I: structure, physiology and its role in risk stratification of angina patients. In: Kaski JC, Holt DW, eds. Myocardial damage: early detection by novel biochemical markers. Doldrecht: Kluwer; 1998: 41–52.
Wu AHB. Use of cardiac markers as assessed by outcomes analysis. Clin Biochem 1997; 30: 339.
Lindhal B, Venge P, Wallentin L. The FRISC experience with troponin T. Eur Heart J 1998; 19 [Suppl N]; N51.
The Capture-Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429.
Hamm CW. Progress in the diagnosis of unstable angina and perspectives for treatment. Eur Heart J 1998; 19 [Suppl N]; N48.
The National Academy of Clinical Biochemistry. Guidelines for the use of cardiac markers in coronary artery diseases. Proceeding of Edutrak at the American Association for Clinical Chemistry 1998 Annual Meeting, Chicago, Il. August 4–5.
Zaninotto M, Altinier S, Lachin M, Celegon L, Plebani M. Strategies for the early diagnosis of acute myocardial infarction using biochemical markers. Am J Clin Pathol 1999; 111: 399.
Zaninotto M, Altinier S, Lachin M, Plebani M. Fluoroenzymometric method for measure cardiac troponin I in sera of patients with myocardial infarction. Clin Chem 1996; 42: 1460.
Jansen RTP, Blaton V, Burnett D, Huisman W, Queraltò JM, Zérah S, Allman B. Additional essential criteria for quality systems of medical laboratories. Clin Chem Lab Med 1998; 36: 249.
Fareed J, Hoppensteadt DA, Leya F, Iqbal O, Wolf H, Bick R. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 1998; 44,8: 1845.
Gargan PE, Gaffney PJ, Pleasants JR, Ploplis VA. A monoclonal antibody which recognized an epitopic region unique to the intact fibrin polymeric structure. Fibrinolysis 1993; 7: 275.
Carville DGM, Dimitrijevic N, Walsh M, Digirolamo T, Brill EM, Drew N, Gargan PE. Thrombus precursor protein (TpPTM): marker of thrombosis early in the pathogenesis of myocardial infarction. Clin Chem 1996; 42: 1537.
Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236.
Ottani F, Galvani M, Ferrini D, Nanni C, Puggioni R, Rusticali F, Eisenberg PR. Concurrent elevations of cross-linked fibrin degradation products identify high-risk of coronary events in patients with acute coronary syndromes and elevated troponin I. Circulation 1997; 96: 332.
Liao JK. Endothelium and acute coronary syndromes. Clin Chem 1998; 44: 1799.
Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228.
Cannon RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 1998; 44: 1809.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973.
Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007.
Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417.
Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430.
Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. Circulation 1997; 96: 4095.
Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 199; 281: 427.